Evofem Biosciences, Inc. (EVFM) › Operating Cash FlowEvofem Biosciences, Inc. (EVFM) — Operating Cash FlowAnnual figures by fiscal year, from SEC filings.2018: -$56.50M2019: -$55.10M2020: -$104.83M2021: -$146.67M2022: -$70.41M2023: -$8.97M2024: -$3.88M2025: -$1.99M-$1.99M2018Operating Cash Flow (USD)2025Fiscal YearOperating Cash FlowChange YoY2025-$1.99M+48.7%2024-$3.88M+56.7%2023-$8.97M+87.3%2022-$70.41M+52.0%2021-$146.67M-39.9%2020-$104.83M-90.3%2019-$55.10M+2.5%2018-$56.50M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per Share